Rate of early treatment discontinuation among a community sample of naive hepatitis C patients on Rebetron combination therapy.

被引：0
|
作者：
Belville-Robertson, TL
Brown, KA
Moonka, DK
Mahr, G
Clemensen, LR
Mankato, N
Lucas, MB
Eshelman, AK
机构：
[1] Henry Ford Hlth Syst, Detroit, MI USA
[2] ISJ Clin Northridge, N Mankato, MN USA
来源：
HEPATOLOGY | 2001年 / 34卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
1716
引用
收藏
页码：601A / 601A
页数：1
相关论文
共 50 条
  • [41] Long duration therapy (96 weeks) reduces relapse rate in chronic hepatitis C patients treated with Rebetron: A pilot study.
    Pimstone, NR
    Balasubramanian, S
    HEPATOLOGY, 2002, 36 (04) : 597A - 597A
  • [42] How to avoid discontinuation of ribavirin in combination with interferon to maintain efficacy of treatment for chronic hepatitis C patients
    Akinori Kasahara
    Journal of Gastroenterology, 2004, 39 : 1125 - 1126
  • [43] A Study to Understand the Reasons for Early Treatment Discontinuation among People Living with Hepatitis C in Punjab, India
    Mutreja, Karishma
    Boeke, Caroline E.
    Tandon, Roli
    Witschi, Magdalena
    Sindhwani, Siddharth
    Chawla, Umesh
    Gaugna, Shalu
    Grover, Gagandeep Singh
    INDIAN JOURNAL OF PUBLIC HEALTH, 2025, 69 (01) : 3 - 9
  • [44] How to avoid discontinuation of ribavirin in combination with interferon to maintain efficacy of treatment for chronic hepatitis C patients
    Kasahara, A
    JOURNAL OF GASTROENTEROLOGY, 2004, 39 (11) : 1125 - 1126
  • [45] Interactions between risk factors for hepatitis C, pre-treatment viral load and response to treatment with combination therapy.
    Gajula, L
    Clark, C
    HEPATOLOGY, 2000, 32 (04) : 566A - 566A
  • [46] Reasons for Treatment (Tx) Discontinuation Among Hepatitis C (HCV) Patients Treated in Clinical Practice
    Yood, Marianne Ulcickas
    Sapra, Sandhya
    Oliveria, Susan A.
    Casso, Deborah
    Fu, An-Chen
    L'Italien, Gilbert
    HEPATOLOGY, 2012, 56 : 1005A - 1005A
  • [47] Combination therapy with interferon alpha-2b and ribavirin in naive patients with chronic hepatitis C
    Juszczyk, J
    Bolewska, B
    Cianciara, J
    Jablonska, J
    Zaborowski, P
    Niedzialek, D
    Gladysz, A
    Piszko, P
    JOURNAL OF HEPATOLOGY, 2000, 32 : 199 - 199
  • [48] WHO 2024 Hepatitis B Guidelines and Treatment-Eligible Rate Among Treatment-Naive Patients
    Wang, Jian
    Zhang, Shaoqiu
    Zhu, Chuanwu
    Wu, Chao
    Huang, Rui
    JAMA NETWORK OPEN, 2024, 7 (09) : e2435777
  • [49] Which combination therapy strategy for "naive" patients with chronic hepatitis C is the most cost-effective?.
    Buti, M
    Casado, MA
    Medina, M
    Fosbrook, L
    Esteban, R
    HEPATOLOGY, 2001, 34 (04) : 426A - 426A
  • [50] Combination treatment with interferon alfa-2b and ribavirin for chronic hepatitis C in patients who have failed interferon therapy.
    Birdi, PK
    Wustrack, S
    Rostetter, E
    King, JW
    Balart, LA
    GASTROENTEROLOGY, 2000, 118 (04) : A1426 - A1426
12345